PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has scheduled its Q1 2025 financial results announcement for May 14, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time.
Key highlights:
- Conference participants are advised to register 5 minutes before the call
- The company's core technology, PLEX (Polymer-Lipid Encapsulation matriX), enables controlled drug release over extended periods
- Their lead product, D-PLEX100, is in Phase 3 trials for preventing abdominal colorectal surgical site infections
- A preclinical candidate, OncoPLEX, is being tested for solid tumor treatment, starting with glioblastoma
The PLEX technology pairs with Active Pharmaceutical Ingredients (APIs) to deliver drugs at optimal release rates, ranging from days to months.
PolyPid (Nasdaq: PYPD), un'azienda biofarmaceutica in fase avanzata focalizzata sul miglioramento degli esiti chirurgici, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 14 maggio 2025, prima dell'apertura dei mercati statunitensi. L'azienda terrà una conferenza telefonica e una webcasting alle 8:30 AM ora orientale.
Punti salienti:
- Si consiglia ai partecipanti alla conferenza di registrarsi 5 minuti prima dell'inizio della chiamata
- La tecnologia principale dell'azienda, PLEX (Polymer-Lipid Encapsulation matriX), permette un rilascio controllato del farmaco per periodi prolungati
- Il prodotto principale, D-PLEX100, è in fase 3 di sperimentazione per la prevenzione delle infezioni del sito chirurgico addominale in interventi colorettali
- Un candidato preclinico, OncoPLEX, è in fase di test per il trattamento di tumori solidi, partendo dal glioblastoma
La tecnologia PLEX si combina con gli Ingredienti Farmaceutici Attivi (API) per somministrare farmaci con tassi di rilascio ottimali, che variano da giorni a mesi.
PolyPid (Nasdaq: PYPD), una compañía biofarmacéutica en etapa avanzada enfocada en mejorar los resultados quirúrgicos, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 14 de mayo de 2025, antes de la apertura de los mercados en EE.UU. La compañía realizará una llamada conferencia y una transmisión web a las 8:30 AM hora del Este.
Puntos clave:
- Se recomienda a los participantes de la conferencia registrarse 5 minutos antes de la llamada
- La tecnología principal de la compañía, PLEX (Polymer-Lipid Encapsulation matriX), permite una liberación controlada de medicamentos durante períodos prolongados
- Su producto principal, D-PLEX100, está en ensayos de fase 3 para prevenir infecciones en el sitio quirúrgico abdominal en cirugías colorrectales
- Un candidato preclínico, OncoPLEX, se está probando para el tratamiento de tumores sólidos, comenzando con glioblastoma
La tecnología PLEX se combina con Ingredientes Farmacéuticos Activos (APIs) para administrar medicamentos a tasas de liberación óptimas, que van desde días hasta meses.
PolyPid (나스닥: PYPD)는 수술 결과 개선에 중점을 둔 후기 단계 바이오제약 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 14일 미국 시장 개장 전에 예정하고 있습니다. 회사는 동부 시간 기준 오전 8시 30분에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
주요 내용:
- 컨퍼런스 참가자는 통화 5분 전에 등록할 것을 권장합니다
- 회사의 핵심 기술인 PLEX (Polymer-Lipid Encapsulation matriX)는 장기간 동안 제어된 약물 방출을 가능하게 합니다
- 주요 제품인 D-PLEX100은 복부 대장 수술 부위 감염 예방을 위한 3상 임상시험 중입니다
- 전임상 후보 물질인 OncoPLEX는 교모세포종을 시작으로 고형 종양 치료를 위해 시험 중입니다
PLEX 기술은 활성 약물 성분(API)과 결합하여 수일에서 수개월에 걸친 최적의 약물 방출 속도를 제공합니다.
PolyPid (Nasdaq : PYPD), une société biopharmaceutique en phase avancée spécialisée dans l'amélioration des résultats chirurgicaux, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 14 mai 2025, avant l'ouverture des marchés américains. La société organisera une conférence téléphonique et une webdiffusion à 8h30, heure de l'Est.
Points clés :
- Il est conseillé aux participants de la conférence de s'inscrire 5 minutes avant le début de l'appel
- La technologie principale de la société, PLEX (Polymer-Lipid Encapsulation matriX), permet une libération contrôlée des médicaments sur de longues périodes
- Le produit phare, D-PLEX100, est en phase 3 d'essais cliniques pour prévenir les infections du site opératoire abdominal lors de chirurgies colorectales
- Un candidat préclinique, OncoPLEX, est testé pour le traitement des tumeurs solides, en commençant par le glioblastome
La technologie PLEX s'associe aux principes actifs pharmaceutiques (API) pour délivrer les médicaments à des taux de libération optimaux, allant de quelques jours à plusieurs mois.
PolyPid (Nasdaq: PYPD), ein Biopharmaunternehmen in der Spätphase, das sich auf die Verbesserung chirurgischer Ergebnisse spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 14. Mai 2025, vor Öffnung der US-Märkte, geplant. Das Unternehmen wird um 8:30 Uhr Eastern Time eine Telefonkonferenz und Webcast abhalten.
Wichtige Punkte:
- Teilnehmer der Konferenz werden gebeten, sich 5 Minuten vor Beginn des Anrufs zu registrieren
- Die Kerntechnologie des Unternehmens, PLEX (Polymer-Lipid Encapsulation matriX), ermöglicht eine kontrollierte Wirkstofffreisetzung über längere Zeiträume
- Das führende Produkt, D-PLEX100, befindet sich in Phase-3-Studien zur Verhinderung von abdominalen kolorektalen Operationsstelleninfektionen
- Ein präklinischer Kandidat, OncoPLEX, wird für die Behandlung solider Tumoren, beginnend mit Glioblastom, getestet
Die PLEX-Technologie kombiniert sich mit aktiven pharmazeutischen Wirkstoffen (APIs), um Medikamente mit optimalen Freisetzungsraten über Zeiträume von Tagen bis Monaten abzugeben.
- Phase 3 clinical trial ongoing for D-PLEX100 in abdominal colorectal surgical site infections
- Proprietary PLEX technology enables controlled drug release over extended periods
- Expanding pipeline with OncoPLEX in preclinical stages for solid tumors treatment
- None.
PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 14, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, May 14, 2025 |
| Time: | 8:30 AM Eastern Time |
| Conference Call: | https://register-conf.media-server.com/register/BI326905131be34ceda978c4ff2ca7a54d |
| Webcast: | https://edge.media-server.com/mmc/p/bqgwfbps |
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
Britchie@lifesciadvisors.com
FAQ
When will PolyPid (PYPD) release Q1 2025 earnings?
How can investors join PolyPid's (PYPD) Q1 2025 earnings call?
What is PolyPid's (PYPD) main product in clinical trials?
What is PolyPid's (PYPD) PLEX technology used for?
What new treatments is PolyPid (PYPD) developing beyond D-PLEX100?
